Compare MXCT & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | IGA |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 152.5M |
| IPO Year | 2021 | N/A |
| Metric | MXCT | IGA |
|---|---|---|
| Price | $0.75 | $9.86 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 51.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,627,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $8.43 |
| 52 Week High | $3.58 | $10.12 |
| Indicator | MXCT | IGA |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 46.16 |
| Support Level | $0.75 | $9.71 |
| Resistance Level | $1.79 | $10.05 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 61.11 | 17.43 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.